ArticleBlood neoplasia2026
Treatment preferences in Waldenström macroglobulinemia: an international discrete choice experiment in 1455 patients.
Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For Waldenström macroglobulinemia (WM), there is currently no uniform therapeutic approach, with options differing in efficacy, administration, and toxicity profiles. Understanding patient preferences is essential for optimizing treatment strategies. The WM-VOICE study used a discrete choice experiment (DCE) to quantify treatment preferences among patients with WM from 5 high-income countries. The DCE, implemented via a web-based survey, comprised 16 choice sets requiring participants to select between 2 hypothetical treatment options, characterized by varying properties. The properties and values ("attributes and levels"), identified through patient interviews, included response duration (2, 4, 6, or 8 years), administration mode (hospital infusions or pills at home), treatment duration (6 months, 2 years, or ongoing), temporary toxicities (grade 0-1, 2, or 3-4), persistent toxicities (grade 0-1 or 2), and risk of secondary malignancies (increased or not). Repeated choice data were analyzed using a panel mixed logit model. A total of 1455 patients with WM participated, with 75% aged 61 to 80 years, 56% male, and 79% previously treated. All attribute levels significantly influenced choices, with preferences consistent across all countries. Response duration and temporary toxicity emerged as the most influential attributes driving treatment preferences, followed by secondary malignancy and persistent toxicity. Administration mode and treatment duration had relatively less impact on decision-making, although there was a preference for oral, fixed-duration therapy. In conclusion, patients with WM prioritize longer response durations and avoidance of severe toxicity, whereas mode of administration and treatment duration are less influential. These insights can support shared decision-making and inform drug development and clinical trial design in WM, within settings with similar health care resources and infrastructure.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.